These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. Canedo-Marroquín G; Saavedra F; Andrade CA; Berrios RV; Rodríguez-Guilarte L; Opazo MC; Riedel CA; Kalergis AM Front Immunol; 2020; 11():569760. PubMed ID: 33362758 [TBL] [Abstract][Full Text] [Related]
6. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Wooding DJ; Bach H Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241 [TBL] [Abstract][Full Text] [Related]
7. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma. Lindholm PF; Ramsey G; Kwaan HC Semin Thromb Hemost; 2020 Oct; 46(7):796-803. PubMed ID: 32526774 [TBL] [Abstract][Full Text] [Related]
8. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2. Patil AM; Göthert JR; Khairnar V Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapies and immunomodulatory approaches in clinical trials - a mini review. Iqbal Yatoo M; Hamid Z; Rather I; Nazir QUA; Bhat RA; Ul Haq A; Magray SN; Haq Z; Sah R; Tiwari R; Natesan S; Bilal M; Harapan H; Dhama K Hum Vaccin Immunother; 2021 Jul; 17(7):1897-1909. PubMed ID: 33577374 [TBL] [Abstract][Full Text] [Related]
10. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. Martinez MA Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082 [TBL] [Abstract][Full Text] [Related]
12. Cellular and Molecular Immunology Approaches for the Development of Immunotherapies against the New Coronavirus (SARS-CoV-2): Challenges to Near-Future Breakthroughs. Melgaço JG; Brito E Cunha D; Azamor T; da Silva AMV; Tubarão LN; Gonçalves RB; Monteiro RQ; Missailidis S; da Costa Neves PC; Ano Bom APD J Immunol Res; 2020; 2020():8827670. PubMed ID: 33426096 [TBL] [Abstract][Full Text] [Related]
13. Perspective on the Role of Antibodies and Potential Therapeutic Drugs to Combat COVID-19. Tandon S; Aggarwal A; Jain S; Shukla S; Chaudhary S Protein J; 2020 Dec; 39(6):631-643. PubMed ID: 33034824 [TBL] [Abstract][Full Text] [Related]
14. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway. D'Abramo A; Vita S; Maffongelli G; Beccacece A; Agrati C; Cimini E; Colavita F; Giancola ML; Cavasio A; Nicastri E; Front Immunol; 2022; 13():911339. PubMed ID: 35711444 [TBL] [Abstract][Full Text] [Related]
15. Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection. Uriu K; Cárdenas P; Muñoz E; Barragan V; Kosugi Y; Shirakawa K; Takaori-Kondo A; ; Sato K J Infect Dis; 2022 Sep; 226(7):1200-1203. PubMed ID: 35176774 [TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic approaches for treatment of COVID-19. Hossein-Khannazer N; Shokoohian B; Shpichka A; Aghdaei HA; Timashev P; Vosough M J Mol Med (Berl); 2020 Jun; 98(6):789-803. PubMed ID: 32494931 [TBL] [Abstract][Full Text] [Related]
17. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. Majumder J; Minko T AAPS J; 2021 Jan; 23(1):14. PubMed ID: 33400058 [TBL] [Abstract][Full Text] [Related]